We evaluated the long term efficacy of insulin Detemir by switching the basal insulin from NPH to Detemir, with the same dose and timing, in this observational study. 103 Japanese type 2 diabetes patients were enrolled in the study, who had continued the maximum daily dose intensive insulin therapy which led basically no hypoglycemia. Finally 81 patients completed the study. Aiming at a fasting blood glucose level of less than 110 mg/d
l, we could increase the average dose of Detemir from 8 units (6-12 units) to 12 units (8-19.5 units), without any increase in weight and frequency of hypoglycemia. HbA1c was improved significantly, and the improvement was maintained for 18 months.
View full abstract